Clinical-stage biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. p53 is the protein expressed from the TP53 gene, the most commonly mutated gene in cancer. We believe that mutant p53 is an attractive therapeutic target due to the high incidence of p53 mutations across a range of cancer types and its involvement in key cellular activities such as apoptosis. Cancer patients with mutant p53 face a significantly inferior prognosis even when treated with the current standard of care, and a large unmet need for these patients remains. Our lead product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes, or MDS, and acute myeloid leukemia, or AML. APR-246 has received Orphan Drug and Fast Track designations from the FDA for MDS, and Orphan Drug designation from the EMA for MDS, AML and ovarian cancer, and we believe APR-246 will be a first-in-class therapy if approved by applicable regulators. We have commenced a pivotal Phase 3 trial of APR-246 with azacitidine for frontline treatment of TP53 mutant MDS and expect initial data from this trial in the second half of 2020. Our pivotal Phase 3 trial is supported by data from two ongoing Phase 1b/2 investigator initiated trials, one in the U.S. and one in France, testing APR-246 with azacitidine as frontline treatment in TP53 mutant MDS and AML patients.
Please sign in first
none
27.5 Thousand total shares from 1 transactions
27.5 Thousand total shares from 1 transactions
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
KORBEL GREGORY ALAN SVP, CHIEF BUSINESS OFFICER |
|
19,502 | 2021-12-01 | 8 |
|
ABRAHMSEN LARS B. SVP, CHIEF SCIENTIFIC OFFICER |
|
49,587 | 2021-10-01 | 3 |
|
ATTAR EYAL C. SVP, CHIEF MEDICAL OFFICER |
|
83,331 | 2021-09-16 | 3 |
|
COIANTE SCOTT M SVP, CHIEF FINANCIAL OFFICER |
|
91,466 | 2021-08-25 | 2 |
|
32,360 | 2021-06-30 | 1 | |
|
27,360 | 2021-06-30 | 1 | |
|
27,360 | 2021-06-30 | 1 | |
|
291,330 | 2021-06-30 | 1 | |
|
27,360 | 2021-06-30 | 1 | |
|
SCHADE CHRISTIAN S CHAIRMAN & CEO |
|
516,660 | 2021-02-25 | 1 |
|
WESSELS GREGORY S. SVP, CHIEF COMMERCIAL OFFICER |
|
82,000 | 2021-02-25 | 1 |
|
No longer subject to file | 2020-12-28 | 0 | |
|
No longer subject to file | 2020-10-05 | 0 | |
|
No longer subject to file | 2020-07-07 | 0 | |
|
|
0 | 2020-06-30 | 0 | |
|
|
0 | 2020-06-30 | 0 | |
|
|
0 | 2020-06-30 | 0 | |
|
2,212,654 | 2020-06-16 | 0 | |
|
No longer subject to file | 2020-05-18 | 0 | |
|
VERSANT VENTURE CAPITAL V, L.P. VERSANT AFFILIATES FUND V, L.P. VERSANT OPHTHALMIC AFFILIATES I, L.P. |
|
No longer subject to file | 2020-04-09 | 0 |
|
|
6,500 | 2019-10-07 | 0 | |
|
VERSANT VENTURES V GP-GP (CANADA), INC. VERSANT VENTURES V (CANADA), L.P. VERSANT VENTURE CAPITAL V (CANADA), LP VERSANT AFFILIATES FUND V, L.P. |
|
2,852,656 | 2019-10-07 | 0 |
|
2,366,104 | 2019-10-07 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-03 17:01:23 -0500 | 2021-12-01 | M | 27,500 | $0.92 | a | 44,667 | direct | 2.965 | 1.8868 | -33.9623 | 14.2857 | 5 | -33.9623 | 31 | ||
| 2021-12-03 17:01:23 -0500 | 2021-12-01 | M | 27,500 | d | 2,335 | direct | ||||||||||
| 2021-12-03 17:01:23 -0500 | 2021-12-01 | S | 27,500 | $3.96 | d | 17,167 | direct | yes | 2.965 | 1.8868 | -33.9623 | 14.2857 | 5 | -33.9623 | 31 |
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|---|---|---|---|
| APREA THERAPEUTICS INC APRE | 2022-01-28 15:45:04 UTC | -1.1064 | 1.1764 | 550000 |
| APREA THERAPEUTICS INC APRE | 2022-01-28 15:15:03 UTC | -1.1064 | 1.1764 | 550000 |
| APREA THERAPEUTICS INC APRE | 2022-01-28 14:45:03 UTC | -1.0658 | 1.1358 | 550000 |
| APREA THERAPEUTICS INC APRE | 2022-01-28 14:15:03 UTC | -1.0658 | 1.1358 | 550000 |
| APREA THERAPEUTICS INC APRE | 2022-01-28 13:45:03 UTC | -1.0658 | 1.1358 | 550000 |
| APREA THERAPEUTICS INC APRE | 2022-01-28 13:15:03 UTC | -1.0658 | 1.1358 | 550000 |
| APREA THERAPEUTICS INC APRE | 2022-01-28 12:45:03 UTC | -1.0658 | 1.1358 | 550000 |
| APREA THERAPEUTICS INC APRE | 2022-01-27 22:15:03 UTC | -1.0659 | 1.1359 | 600000 |
| APREA THERAPEUTICS INC APRE | 2022-01-27 21:45:03 UTC | -1.0659 | 1.1359 | 600000 |
| APREA THERAPEUTICS INC APRE | 2022-01-27 21:15:03 UTC | -1.0659 | 1.1359 | 600000 |
| APREA THERAPEUTICS INC APRE | 2022-01-27 20:45:03 UTC | -1.0659 | 1.1359 | 600000 |
| APREA THERAPEUTICS INC APRE | 2022-01-27 20:15:04 UTC | -1.0659 | 1.1359 | 600000 |
| APREA THERAPEUTICS INC APRE | 2022-01-27 19:45:03 UTC | -1.0659 | 1.1359 | 600000 |
| APREA THERAPEUTICS INC APRE | 2022-01-27 19:15:03 UTC | -1.0659 | 1.1359 | 600000 |
| APREA THERAPEUTICS INC APRE | 2022-01-27 18:45:03 UTC | -1.0659 | 1.1359 | 600000 |
| APREA THERAPEUTICS INC APRE | 2022-01-27 18:15:03 UTC | -1.0659 | 1.1359 | 600000 |
| APREA THERAPEUTICS INC APRE | 2022-01-27 17:45:03 UTC | -1.0659 | 1.1359 | 600000 |
| APREA THERAPEUTICS INC APRE | 2022-01-27 17:15:03 UTC | -1.0659 | 1.1359 | 600000 |
| APREA THERAPEUTICS INC APRE | 2022-01-27 16:45:03 UTC | -1.029 | 1.099 | 600000 |
| APREA THERAPEUTICS INC APRE | 2022-01-27 16:15:03 UTC | -1.029 | 1.099 | 600000 |
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|---|---|---|---|
| FundVantage Trust- Gotham Enhanced Index Plus Fund | APRE | -2.0 shares, $-69.52 | 2020-03-31 | N-PORT |
| FundVantage Trust- Gotham Index Plus All-Cap Fund | APRE | -2.0 shares, $-69.52 | 2020-03-31 | N-PORT |
| Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | APRE | -100.0 shares, $-511.0 | 2021-09-30 | N-PORT |
